Please assess the completion status of the following clinical trial:

Trial Title: PH III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Previously Untreated Multiple Myeloma (ELO 1 Substudy)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
For more information regarding BMS clinical trial participation, please visit www.BMSStudyConnect.com.~Inclusion Criteria:~Subjects who are newly diagnosed with symptomatic MM and who:~* Have not received any prior systemic anti-myeloma therapy~* Have measurable disease~* And are not candidates for high-dose therapy plus stem-cell transplantation (SCT) because of age (≥65 years) or coexisting conditions. Refusal to undergo high dose therapy with SCT is NOT sufficient for entry onto CA204-006 for a subject \<65 years old. There must be a comorbidity that prevents SCT for a subject \<65 years old~Exclusion Criteria:~* Subjects with non-secretory or oligo-secretory or free light-chain only myeloma~* Smoldering MM, defined as asymptomatic MM with absence of lytic bone lesions~* Monoclonal Gammopathy of Undetermined Significance (MGUS)~* Active plasma cell leukemia~* Known Human Immunodeficiency Virus (HIV) infection or active hepatitis A, B, or C

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Arm 1: Lenalidomide + Dexamethasone (Type: EXPERIMENTAL): Lenalidomide 25 mg capsules by mouth once daily (on Days 1-21), repeat every 28 days until subject meets criteria for discontinuation of study drug~Dexamethasone 40 mg tablets by mouth weekly (on Days 1, 8, 15, 22), repeat every 28 days until subject meets criteria for discontinuation of study drug
- Arm 2: Lenalidomide + Dexamethasone + Elotuzumab (Type: EXPERIMENTAL): Lenalidomide 25 mg capsules by mouth once daily (Days 1-21)~Dexamethasone 28 mg tablets by mouth once daily \[Days 1, 8, 15, 22 (cycles 1 \& 2); Days 1 \& 15(cycles 3-18); Day 1 (cycle 19 \& beyond)\]~Dexamethasone 40 mg tablets by mouth once daily \[Days 8 \& 22 (cycles 3-18); Days 8, 15, 22 (cycle 19 \& beyond)\]~Dexamethasone 8 mg IV (intravenous) solution once daily \[Days 1, 8, 15, 22 (cycles 1 \& 2); Days 1 \& 15 (cycles 3-18); Day 1 (cycle 19 \& beyond)\]~Elotuzumab 10 mg/kg IV solution weekly \[Days 1, 8, 15, 22 (cycles 1 \& 2); Days 1 \& 15 (cycles 3-18)\]~Elotuzumab 20 mg/kg IV solution on Day 1 (cycle 19 \& beyond)~Repeat above-mentioned dose cycles every 28 days until subject meets criteria for discontinuation of study drug

Based on this trial design, predict the completion outcome and termination type (if applicable).